## **AMENDMENT**


## Claim Listing\_

- 1. (presently amended) A compound comprising a steroid hormone <u>selected</u> from the group consisting of glucocorticoids, mineralcorticoids, androgens and estrogens, <u>said steroid hormone being</u> stably linked <u>via a spacer of 5-15 atoms</u> to a <u>DNA-incorporating</u> <u>DNA-interacting</u> molecule, wherein the steroid hormone is linked via a first urethane bond to the spacer and the spacer is linked via a second urethane bond to the DNA-incorporating molecule.
  - 2-5. (canceled)
  - 6. (original) The compound of claim 1, wherein the spacer contains 5-15 atoms.
  - 7. (original) The compound of claim 1, wherein the spacer contains 9-11 atoms.
  - 8. (canceled)
- 9. (original) The compound of claim 4, wherein the steroid hormone is linked via a first urethane bond to the spacer and the spacer is linked via a second urethane bond to the DNA-interacting molecule.
- 10. (presently amended) The compound of claim 1, wherein the urethane bond is positioned either at carbon atom[s] 1, 2, 4, 6, 7, 11α [11a], 12, 15, 16, 17 or 21 of the [a] glucocorticoid.
- bond is positioned either at carbon atom 6 or 21 of the [a] glucocorticoid.
  - 12-13. (canceled)
- 14. (presently amended) The compound of claim 1 [13], wherein the <u>DNA-incorporating</u> [DNA-interacting] molecule is a <u>psoralen</u> [selected from the group consisting of intercalating agents, crosslinking reagents, incorporating molecules and ionically interacting molecules].
  - 15-16. (canceled)
- 17. (presently amended) A method for the preparation of the compound according to claim 1 comprising the steps of ligating a spacer of 5-15 atoms to the steroid



hormone <u>via an urethane bond and ligating the DNA-incorporating</u> [to a DNA-interacting] molecule via an urethane bond to the spacer.

- 18-19. (canceled)
- 20. (withdrawn) A complex consisting of a compound of claim 1 commplexed to a nucleic acid molecule.
- 21. (withdrawn) A method for the preparation of the complex of claim 20 comprising the steps of ligating a steroid hormone to a DNA-interacting molecule to form a compound and complexing the compound with a nucleic acid molecule.
- 22. (withdrawn) The method of claim 21 further comprising the steps of ligating a spacer to the steroid hormone and ligating the DNA-interacting molecule to the spacer.
- 23. (withdrawn) Use of the complex of claim 20 for introducing a nucleic acid molecule into the nucleus of a cell.
- 24. (withdrawn) Use of the complex of claim 20 for introducing a DNA molecule into the nucleus of a non-dividing cell.
  - 25. (withdrawn) A cell transfected with a complex according to claim 20.
- 26. (withdrawn) Use of a cell according to claim 25 for the medical treatment of a human being.
- 27. (withdrawn) A pharmaceutical preparation comprising the complex of claim 20 and a physiologically tolerable carrier.
- 28. (withdrawn) A method for transfecting cells comprising the step of administering a therapeutically effective amount of a complex according to claim 20 to a subject.
  - 29. (withdrawn) An assay comprising the steps of
- a) transfecting cells with a complex of claim 20, wherein the DNA molecule contains an expressible gene;
  - b) monitoring the expression of said expressible gene, and
- c) comparing the expression of said expressible gene in transfected cells with the expression of said expressible gene in non-transfected cells.
  - 30. (original) The compound of claim 1, wherein the spacer contains 10 atoms.



- 32. (new) The compound of claim 1, wherein the steroid hormone is a glucocorticoid hormone.
- 33. (new) The compound of claim 2, wherein the glucocorticoid hormone is selected from dexamethasone and cortisol.